Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologySupportive CareTrial Update

Feasibility Study of RestoreMe App for Cancer Patient Nutrition and Activity

The feasibility study of the RestoreMe app represents a significant step in integrating digital health solutions into oncology care. If successful, it could pave the way for larger trials and establish the app as a leader in personalized cancer supportive care.

Published: July 3, 2026
Updated: July 3, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Supportive Care
Asset: Feasibility
Indication: cancer patients
Trial SummaryCLN

Phase III

cancer patients

Status

Active

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Strategic implication

The feasibility study of the RestoreMe app represents a significant step in integrating digital health solutions into oncology care. If successful, it could pave the way for larger trials and establish the app as a leader in personalized cancer supportive care.

Why it matters

The feasibility study of the RestoreMe app represents a significant step in integrating digital health solutions into oncology care. If successful, it could pave the way for larger trials and establish the app as a leader in personalized cancer supportive care.

What changed

Trial Update

Analysis

Montefiore Medical Center is conducting a feasibility study to assess the RestoreMe app for cancer patients, recruiting 150 participants.

The feasibility study of the RestoreMe app represents a significant step in integrating digital health solutions into oncology care. If successful, it could pave the way for larger trials and establish the app as a leader in personalized cancer supportive care.

Monitor recruitment progress and outcomes from the feasibility study to gauge future trial designs.

Related companies & assets

Assets

  • Feasibility →

Sources & Humanexa intelligence

Source links

  • Feasibility Study of RestoreMe App for Cancer Patient Nutrition and Activity ↗

Related Humanexa pages

  • Feasibility Study of RestoreMe App for Cancer Patient Nutrition and Activity →

Related signals

Trial SummaryCLN

Phase III

Immunology / Systemic Lupus Erythematosus

Status

Active

Sponsor

Eisai Co., Ltd.

Signal Score

8.2

Clinicalhigh signal

Eisai's E6742 Shows Promise in Systemic Lupus Erythematosus Study

E6742 is being evaluated for efficacy in systemic lupus erythematosus compared to placebo, with results expected at Week 24.

July 4, 2026Read signal →
Trial SummaryCLN

Phase III

B-cell Non-Hodgkin Lymphoma therapies

Status

Active

Signal Score

8.2

Clinicalhigh signal

Study on CD3-CD20 Bispecific Antibody with CD19-CAR T Cells in B-NHL

A clinical study is underway to evaluate the safety and efficacy of CD3-CD20 bispecific antibody therapy combined with CD19-CAR T cells in relapsed refractory B-NHL.

July 4, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.